InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

InflaRx N.V.NASDAQ: IFRX

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was €0, compared with €0 a year earlier. Trailing-twelve-month income tax expense was €12.28K.

Context

  • Income tax expense amounted to 41.9% of revenue in FY2025, up 38.7 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near €0 or moves back toward the trailing-twelve-month quarterly average of €3.07K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
€0— QoQ
Last fiscal yearDec 2025
€12.28K+135.4% YoY
LTMMar 2026
€12.28K+135.4% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+135.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

EUR · from the income statement

Latest · FY2025
12.28K EUR
Year-over-year change
+135.4%

Income Tax Expense vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +135.4% is the highest of 4, against a peer median of -104.9%.
  • Income tax expense amounts to 41.9% of revenue for IFRX, versus a peer median of 0.1%.
IFRX Competitors
Income Tax Expense for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CNTBConnect Biopharma Holdings LimitedFY2025$197K USD-11.7%-12.9%307.8%
IFRXInflaRx N.V.LTM Mar 2026€12.28K EUR+135.4%—41.9%
STTKShattuck Labs, Inc.LTM Mar 2026$0 USD——0.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD———
KLRSKalaris Therapeutics IncLTM Mar 2026$0 USD———
CNTXContext Therapeutics Inc.LTM Mar 2026$0 USD———
ATYRaTyr Pharma, Inc.LTM Mar 2026$0 USD——0.0%
STROSutro Biopharma, Inc.LTM Mar 2026-$115K USD-104.9%—0.1%
IMAImageneBio IncLTM Mar 2026-$325K USD-312.4%——
Peer median (excluding IFRX) —-104.9%-12.9%0.1%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0063.09K165.79K29.33K
Cost of Revenue00532.26K3.32M7.27M
Gross Profit00(469.17K)(3.15M)(7.24M)
Gross Margin——-743.7%-1900.8%-24677.9%
Research & Development35.7M37.53M41.02M35.36M25.72M
Selling, General & Admin11.43M14.34M16.12M19.33M17.56M
Operating Expenses47.63M32.24M44.13M49.75M41.02M
Depreciation & Amortization669.43K596.6K567.78K485.11K419.48K
EBITDA(44.94M)(28.84M)(42.06M)(45.55M)(45.16M)
EBITDA Margin——-66674.3%-27476.7%-153976.3%
Operating Income(47.63M)(32.24M)(44.59M)(52.91M)(48.26M)
Operating Margin——-70685.6%-31911.4%-164525.5%
Interest Income109.39K608.68K3.8M3.2M1.77M
Interest Expense24.77K45.25K35.63K20.66K37.69K
Other Income / Expenses2M2.75M1.93M6.85M2.64M
Income Before Tax(45.63M)(29.48M)(42.67M)(46.06M)(45.62M)
Pre-Tax Margin——-67630.7%-27781.8%-155540.2%
Income Tax Expense0005.22K12.28K
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(45.63M)
Net Margin——-67630.7%-27785.0%-155582.1%
EPS (Basic)(1.10)(0.61)(0.78)(0.78)(0.66)
EPS (Diluted)(1.10)(0.61)(0.78)(0.78)(0.66)
Weighted Avg Shares41.63M44.21M54.94M58.92M67.29M
Weighted Avg Shares (Diluted)41.63M44.21M54.94M58.92M67.29M

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.